欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子化合物 > 小分子抑制剂 > Rabusertib

商品分类

浏览历史

S51755

Rabusertib

MedMol 98%
  • 英文名:
  • Rabusertib
  • 别名:
  • Rabusertib;LY2603618;IC-83
  • CAS号:
  • 911222-45-2
  • 分子式:
  • C18H22BrN5O3
  • 分子量:
  • 436.3
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
MedMol S51755-5mg 98% ¥480.00元 预计交期:3-5天 0 0 0 EA 加入购物车
MedMol S51755-10mg 98% ¥780.00元 预计交期:3-5天 0 0 0 EA 加入购物车
MedMol S51755-25mg 98% ¥1560.00元 预计交期:3-5天 0 0 0 EA 加入购物车
MedMol S51755-100mg 98% ¥4300.00元 预计交期:3-5天 0 0 0 EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 产品描述:

    Rabusertib (LY2603618) 是一种有效的选择性的 Chk1 抑制剂,IC50 为 7 nM。

  • 靶点: Chk1:7 nM (IC50);Chk2:12000 nM (IC50);PDK1:893 nM (IC50)
  • 体外研究: Rabusertib (LY2603618) is a highly effective inhibitor of multiple aspects of Chk1 biology. Rabusertib (LY2603618) is tested against a panel of 51 diverse protein kinases in vitro. With an IC50 of 7 nM for Chk1, Rabusertib (LY2603618) is approximately 100-fold more potent against Chk1 than against any of the other protein kinases evaluated (PDK1, IC50=893 nM, others >1000 nM). Rabusertib (LY2603618) effectively reduced Chk1 autophosphorylation with an EC50 of 430 nM. Inhibition of Chk1 by Rabusertib (LY2603618) also effectively abrogated the G2/M DNA damage checkpoint in cells treated with DNA damaging agents. Treatment of cells with Rabusertib (LY2603618) produced a cellular phenotype similar to that reported for depletion of Chk1 by RNAi. Inhibition of intracellular Chk1 by Rabusertib (LY2603618) results in impaired DNA synthesis, elevated H2A.X phosphorylation indicative of DNA damage and premature entry into mitosis. Treatments of the SK-N-BE(2) cells with variable concentrations of Rabusertib (LY2603618) results in dose-dependent inhibition of cell growth determined by MTT assays with an IC50 of 10.81 µM
  • 体内研究: Mice bearing Calu-6 xenografts are treated with 150 mg/kg (IP) Gemcitabine and a single simultaneous 200 mg/kg oral dose of Rabusertib (LY2603618). 200 mg/kg of Rabusertib (LY2603618) is sufficient to inhibit 85 % of Chk1 autophosphorylation in vivo at 2 h. Rabusertib (LY2603618) effectively reduces Gemcitabine-induced phosphorylation on Tlk serine 695 as well, supporting the cited report with a selective chemical inhibitor of Chk1.
  • 参考文献:
    1. King C, et al. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.

    2. Wang G, et al. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. PLoS One. 2013 Sep 30;8(9):e76662.
  • 溶解性: soluble  in  DMSO
  • 保存条件: -20℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 2.292 ml 11.46 ml 22.92 ml
    5 mM 0.458 ml 2.292 ml 4.584 ml
    10 mM 0.229 ml 1.146 ml 2.292 ml
    50 mM 0.046 ml 0.229 ml 0.458 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。